Skip to main content

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

Pharma courses

pharma courses

NATCO receives Emergency Use approval for Baricitinib tablets for Covid-19 treatment

Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients.

Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. This paper is published at New England journal of medicine.

Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic. The company is ready to launch the product this week, so as to make the product available to suffering patients across India.

<< Back to Pharma News


Subscribe to PharmaTutor News Alerts by Email

Search this website